open access

Vol 67, No 2 (2016)
Review article
Published online: 2016-02-17
Submitted: 2015-11-13
Accepted: 2015-11-30
Get Citation

Mouse models of papillary thyroid carcinoma — short review

Dagmara Rusinek, Jolanta Krajewska, Michał Jarząb
DOI: 10.5603/EP.a2016.0042
·
Endokrynologia Polska 2016;67(2):212-223.

open access

Vol 67, No 2 (2016)
Review article
Published online: 2016-02-17
Submitted: 2015-11-13
Accepted: 2015-11-30

Abstract

Thyroid carcinoma (TC) is the most common endocrine malignancy, and its frequency is still rising. Papillary thyroid carcinoma (PTC) accounts for 80% of all TCs and usually is related to a very good prognosis. However, the standard therapeutic approaches are not always sufficient and disease progression is sometimes observed. These data highlight the limitation of our understanding of molecular mechanisms underlying tumorigenesis and how they vary between individual patients. Over the last 19 years mouse models of thyroid cancers have been developed in order to give answers to questions about their genetic background, relations of key molecular events with pathways fundamental for cancer, and many others. Among these models genetically engineered mice were of utmost importance regarding the input of knowledge about human tumorigenesis. In the present review the most significant mouse models of PTC are described with particular emphasis on BRAFV600E-induced ones, for the sake of its frequency in PTC, relation to factors of poor prognosis, and the fact that, since its identification, it became an attractive target in novel therapies. For the presented mouse models phenotype consequences of particular genetic alterations are described as well as the limitations of the used methods. (Endokrynol Pol 2016; 67 (2): 212–223)

Abstract

Thyroid carcinoma (TC) is the most common endocrine malignancy, and its frequency is still rising. Papillary thyroid carcinoma (PTC) accounts for 80% of all TCs and usually is related to a very good prognosis. However, the standard therapeutic approaches are not always sufficient and disease progression is sometimes observed. These data highlight the limitation of our understanding of molecular mechanisms underlying tumorigenesis and how they vary between individual patients. Over the last 19 years mouse models of thyroid cancers have been developed in order to give answers to questions about their genetic background, relations of key molecular events with pathways fundamental for cancer, and many others. Among these models genetically engineered mice were of utmost importance regarding the input of knowledge about human tumorigenesis. In the present review the most significant mouse models of PTC are described with particular emphasis on BRAFV600E-induced ones, for the sake of its frequency in PTC, relation to factors of poor prognosis, and the fact that, since its identification, it became an attractive target in novel therapies. For the presented mouse models phenotype consequences of particular genetic alterations are described as well as the limitations of the used methods. (Endokrynol Pol 2016; 67 (2): 212–223)

Get Citation

Keywords

mouse model; papillary thyroid carcinoma; BRAFV600E

About this article
Title

Mouse models of papillary thyroid carcinoma — short review

Journal

Endokrynologia Polska

Issue

Vol 67, No 2 (2016)

Pages

212-223

Published online

2016-02-17

DOI

10.5603/EP.a2016.0042

Bibliographic record

Endokrynologia Polska 2016;67(2):212-223.

Keywords

mouse model
papillary thyroid carcinoma
BRAFV600E

Authors

Dagmara Rusinek
Jolanta Krajewska
Michał Jarząb

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl